Literature DB >> 3487256

Bronchial histamine challenge in the diagnosis of asthma. The predictive value of changes in airway resistance determined by the interrupter method.

F Madsen, N H Holstein-Rathlou, L Frølund, B Weeke, U G Svendsen.   

Abstract

The predictive value of a bronchial challenge with histamine was determined in a prospective survey on a population with a high prevalence of asthma (0.62). Without knowledge of the bronchial responsiveness 133 patients were classified as asthmatics (83) or non-asthmatics (50) according to variation in peak expiratory flow rate and medical history. Response to challenge was determined by the interrupter method, and the concentration of histamine inducing a 40% increase in resistance to breathing (PC40-Rt) was calculated from the log dose response curve. When defining a positive test as a test giving PC40-Rt-values below 2.00 mg/ml, the predictive value of a positive test was 0.75 and the predictive value of a negative test was 0.72. By decreasing the limit for a positive test to 0.25 mg/ml the corresponding predictive value was increased to 0.91. When further increasing the limit to 4.00 mg/ml the predictive value of a negative test in the diagnosis of asthma was increased to 0.81. The interrupter technique is suitable for diagnostic purposes in the detection and exclusion of bronchial asthma.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3487256     DOI: 10.1111/j.1398-9995.1986.tb00299.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  3 in total

Review 1.  Bronchial challenges.

Authors:  H Chai
Journal:  Clin Rev Allergy       Date:  1988

2.  Small airway hyperreactivity among lifelong non-atopic non-smokers exposed to isocyanates.

Authors:  U Hjortsberg; P Orbaek; M Arborelius
Journal:  Br J Ind Med       Date:  1987-12

3.  Use of interrupter technique in assessment of bronchial responsiveness in normal subjects.

Authors:  Panagiotis Panagou; Ioannis Kottakis; Argyris Tzouvelekis; Stavros Anevlavis; Demosthenes Bouros
Journal:  BMC Pulm Med       Date:  2004-11-12       Impact factor: 3.317

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.